BACKGROUND: To our knowledge, no randomized toxicity studies have been conducted to compare myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) in allogeneic haematopoietic stem cell transplantation (HSCT). METHODS:Adult patients ≤60 years of age with myeloid leukaemia were randomly assigned (1 : 1) to treatment with RIC (n = 18) or MAC (n = 19) in this Phase II single-centre toxicity study. RESULTS: There was a maximum median mucositis grade of 1 in the RIC group compared with 4 in the MAC group (P < 0.001). Haemorrhagic cystitis occurred in eight of the patients in the MAC group and none in the RIC group (P < 0.01). Results of renal and hepatic tests did not differ significantly between the two groups. RIC-treated patients had faster platelet engraftment (P < 0.01) and required fewer erythrocyte and platelet transfusions (P < 0.001) and less total parenteral nutrition (TPN) than those treated with MAC (P < 0.01). Cytomegalovirus (CMV) infection was more common in the MAC group (14/19) than in the RIC group (6/18) (P = 0.02). Donor chimerism was similar in the two groups with regard to CD19 and CD33, but was delayed for CD3 in the RIC group. Five-year transplant-related mortality (TRM) was approximately 11% in both groups, and rates of relapse and survival were not significantly different. Patients in the MAC group with intermediate cytogenetic acute myeloid leukaemia had a 3-year survival of 73%, compared with 90% among those in the RIC group. CONCLUSION: Reduced-intensity conditioning had several advantages compared with MAC, including less mucositis, less haemorrhagic cystitis, faster platelet engraftment, the need for fewer transfusions and less TPN, and fewer CMV infections. Both regimens were tolerated and TRM was low.
RCT Entities:
BACKGROUND: To our knowledge, no randomized toxicity studies have been conducted to compare myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) in allogeneic haematopoietic stem cell transplantation (HSCT). METHODS: Adult patients ≤60 years of age with myeloid leukaemia were randomly assigned (1 : 1) to treatment with RIC (n = 18) or MAC (n = 19) in this Phase II single-centre toxicity study. RESULTS: There was a maximum median mucositis grade of 1 in the RIC group compared with 4 in the MAC group (P < 0.001). Haemorrhagic cystitis occurred in eight of the patients in the MAC group and none in the RIC group (P < 0.01). Results of renal and hepatic tests did not differ significantly between the two groups. RIC-treated patients had faster platelet engraftment (P < 0.01) and required fewer erythrocyte and platelet transfusions (P < 0.001) and less total parenteral nutrition (TPN) than those treated with MAC (P < 0.01). Cytomegalovirus (CMV) infection was more common in the MAC group (14/19) than in the RIC group (6/18) (P = 0.02). Donor chimerism was similar in the two groups with regard to CD19 and CD33, but was delayed for CD3 in the RIC group. Five-year transplant-related mortality (TRM) was approximately 11% in both groups, and rates of relapse and survival were not significantly different. Patients in the MAC group with intermediate cytogenetic acute myeloid leukaemia had a 3-year survival of 73%, compared with 90% among those in the RIC group. CONCLUSION: Reduced-intensity conditioning had several advantages compared with MAC, including less mucositis, less haemorrhagic cystitis, faster platelet engraftment, the need for fewer transfusions and less TPN, and fewer CMV infections. Both regimens were tolerated and TRM was low.
Authors: J R Passweg; M Labopin; J Cornelissen; L Volin; G Socié; A Huynh; R Tabrizi; D Wu; C Craddock; N Schaap; J Kuball; P Chevallier; J Y Cahn; D Blaise; A Ghavamzadeh; K Bilger; F Ciceri; C Schmid; S Giebel; A Nagler; M Mohty Journal: Bone Marrow Transplant Date: 2015-06-01 Impact factor: 5.483
Authors: Olle Ringdén; Ruta Brazauskas; Zhiwei Wang; Ibrahim Ahmed; Yoshiko Atsuta; David Buchbinder; Linda J Burns; Jean-Yves Cahn; Christine Duncan; Gregory A Hale; Joerg Halter; Robert J Hayashi; Jack W Hsu; David A Jacobsohn; Rammurti T Kamble; Naynesh R Kamani; Kimberly A Kasow; Nandita Khera; Hillard M Lazarus; Alison W Loren; David I Marks; Kasiani C Myers; Muthalagu Ramanathan; Wael Saber; Bipin N Savani; Harry C Schouten; Gérard Socie; Mohamed L Sorror; Amir Steinberg; Uday Popat; John R Wingard; Jonas Mattsson; Navneet S Majhail Journal: Biol Blood Marrow Transplant Date: 2014-07-17 Impact factor: 5.742
Authors: Celalettin Ustun; Soyoung Kim; Min Chen; Amer M Beitinjaneh; Valerie I Brown; Parastoo B Dahi; Andrew Daly; Miguel Angel Diaz; Cesar O Freytes; Siddhartha Ganguly; Shahrukh Hashmi; Gerhard C Hildebrandt; Hillard M Lazarus; Taiga Nishihori; Richard F Olsson; Kristin M Page; Genovefa Papanicolaou; Ayman Saad; Sachiko Seo; Basem M William; John R Wingard; Baldeep Wirk; Jean A Yared; Miguel-Angel Perales; Jeffery J Auletta; Krishna V Komanduri; Caroline A Lindemans; Marcie L Riches Journal: Blood Adv Date: 2019-09-10
Authors: Karin Garming Legert; Georgios Tsilingaridis; Mats Remberger; Olle Ringdèn; Anders Heimdahl; Tülay Yucel-Lindberg; Göran Dahllöf Journal: Support Care Cancer Date: 2014-11-30 Impact factor: 3.603
Authors: A A Hamidieh; M Behfar; Z Pourpak; S Faghihi-Kashani; M R Fazlollahi; A S Hosseini; M Movahedi; M Mozafari; M Moin; A Ghavamzadeh Journal: Bone Marrow Transplant Date: 2015-11-23 Impact factor: 5.483
Authors: Erica D Warlick; Kristjan Paulson; Ruta Brazauskas; Xiaobo Zhong; Alan M Miller; Bruce M Camitta; Biju George; Bipin N Savani; Celalettin Ustun; David I Marks; Edmund K Waller; Frédéric Baron; César O Freytes; Gérard Socie; Gorgun Akpek; Harry C Schouten; Hillard M Lazarus; Edwin M Horwitz; John Koreth; Jean-Yves Cahn; Martin Bornhauser; Matthew Seftel; Mitchell S Cairo; Mary J Laughlin; Mitchell Sabloff; Olle Ringdén; Robert Peter Gale; Rammurti T Kamble; Ravi Vij; Usama Gergis; Vikram Mathews; Wael Saber; Yi-Bin Chen; Jane L Liesveld; Corey S Cutler; Armin Ghobadi; Geoffrey L Uy; Mary Eapen; Daniel J Weisdorf; Mark R Litzow Journal: Biol Blood Marrow Transplant Date: 2013-11-01 Impact factor: 5.742